IBIO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- iBio reported a single dose of IBIO-610 achieved near-complete Activin E inhibition for eight weeks in an obesity studyJul 1, 2026
- iBio received regulatory clearance to start Phase 1 trial of IBIO-600 in AustraliaApr 8, 2026
- iBio reported preclinical data showing body composition improvements in obese primates treated with IBIO-610 for selective fat lossMar 9, 2026
- iBio unveils new non-human primate data on IBIO-610, an Activin E antibody with strong therapeutic potential for fat-selective weight-loss and weight maintenanceOct 30, 2025